Mereo BioPharma Group PLCNASDAQ:MREO
- LAST PRICE4.0200
- TODAY'S CHANGE (%)-0.2600 (-6.0748%)
- Bid / Lots4.0000/ 100
- Ask / Lots4.0300/ 3
- Open / Previous Close4.2400 / 4.2800
- Day Range
- 52 Week Range
- Volume770,963
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MREO |
|---|---|---|
| 09:32 ET | 3723 | 4.24 |
| 09:35 ET | 3100 | 4.195 |
| 09:37 ET | 320 | 4.19 |
| 09:39 ET | 1000 | 4.17 |
| 09:42 ET | 1100 | 4.16 |
| 09:44 ET | 3361 | 4.145 |
| 09:46 ET | 100 | 4.14 |
| 09:48 ET | 900 | 4.1601 |
| 09:50 ET | 402 | 4.155 |
| 09:51 ET | 5548 | 4.145 |
| 09:53 ET | 2400 | 4.17 |
| 09:57 ET | 6345 | 4.16 |
| 10:00 ET | 2100 | 4.1501 |
| 10:02 ET | 2400 | 4.15 |
| 10:04 ET | 1500 | 4.17 |
| 10:08 ET | 1500 | 4.1599 |
| 10:09 ET | 5600 | 4.155 |
| 10:11 ET | 781 | 4.155 |
| 10:13 ET | 1793 | 4.175 |
| 10:15 ET | 200 | 4.18 |
| 10:18 ET | 200 | 4.17 |
| 10:20 ET | 525 | 4.17 |
| 10:22 ET | 200 | 4.17 |
| 10:24 ET | 664 | 4.175 |
| 10:26 ET | 500 | 4.175 |
| 10:27 ET | 2081 | 4.185 |
| 10:29 ET | 1400 | 4.175 |
| 10:31 ET | 7197 | 4.16 |
| 10:33 ET | 100 | 4.17 |
| 10:36 ET | 300 | 4.17 |
| 10:38 ET | 3440 | 4.17 |
| 10:40 ET | 600 | 4.17 |
| 10:42 ET | 1152 | 4.17 |
| 10:44 ET | 1000 | 4.18 |
| 10:45 ET | 200 | 4.17 |
| 10:47 ET | 100 | 4.17 |
| 10:49 ET | 813 | 4.18 |
| 10:54 ET | 4064 | 4.1901 |
| 10:56 ET | 626 | 4.19 |
| 11:00 ET | 402 | 4.19 |
| 11:02 ET | 100 | 4.18 |
| 11:03 ET | 200 | 4.19 |
| 11:05 ET | 2850 | 4.17 |
| 11:07 ET | 200 | 4.175 |
| 11:09 ET | 1219 | 4.175 |
| 11:12 ET | 400 | 4.175 |
| 11:14 ET | 9886 | 4.175 |
| 11:16 ET | 3999 | 4.18 |
| 11:18 ET | 500 | 4.175 |
| 11:20 ET | 1150 | 4.155 |
| 11:21 ET | 1800 | 4.145 |
| 11:23 ET | 2240 | 4.145 |
| 11:25 ET | 36509 | 4.0925 |
| 11:27 ET | 6488 | 4.05 |
| 11:30 ET | 18881 | 4.08 |
| 11:32 ET | 29426 | 4.09 |
| 11:34 ET | 5040 | 4.0895 |
| 11:36 ET | 200 | 4.08 |
| 11:38 ET | 2900 | 4.07 |
| 11:39 ET | 3599 | 4.07 |
| 11:41 ET | 7910 | 4.09 |
| 11:43 ET | 13841 | 4.055 |
| 11:45 ET | 11925 | 4.0325 |
| 11:48 ET | 5771 | 4.0499 |
| 11:50 ET | 2100 | 4.055 |
| 11:52 ET | 200 | 4.05 |
| 11:54 ET | 8188 | 4.05 |
| 11:56 ET | 600 | 4.0479 |
| 11:57 ET | 300 | 4.045 |
| 11:59 ET | 700 | 4.045 |
| 12:01 ET | 550 | 4.045 |
| 12:03 ET | 1110 | 4.05 |
| 12:06 ET | 1600 | 4.0599 |
| 12:08 ET | 1198 | 4.0508 |
| 12:10 ET | 8280 | 4.045 |
| 12:12 ET | 3350 | 4.0499 |
| 12:14 ET | 3626 | 4.045 |
| 12:15 ET | 2710 | 4.0599 |
| 12:17 ET | 12177 | 4.06 |
| 12:19 ET | 100 | 4.051 |
| 12:21 ET | 600 | 4.06 |
| 12:24 ET | 2403 | 4.06 |
| 12:26 ET | 2950 | 4.0699 |
| 12:28 ET | 5265 | 4.07 |
| 12:30 ET | 22280 | 4.06 |
| 12:32 ET | 1652 | 4.065 |
| 12:33 ET | 1100 | 4.065 |
| 12:35 ET | 3100 | 4.065 |
| 12:37 ET | 350 | 4.065 |
| 12:39 ET | 1100 | 4.065 |
| 12:42 ET | 300 | 4.06 |
| 12:44 ET | 1600 | 4.055 |
| 12:46 ET | 950 | 4.05 |
| 12:48 ET | 805 | 4.055 |
| 12:50 ET | 2640 | 4.05 |
| 12:51 ET | 12729 | 4.06 |
| 12:53 ET | 460 | 4.068 |
| 12:55 ET | 1280 | 4.08 |
| 12:57 ET | 300 | 4.08 |
| 01:00 ET | 100 | 4.08 |
| 01:02 ET | 200 | 4.085 |
| 01:04 ET | 500 | 4.085 |
| 01:06 ET | 200 | 4.085 |
| 01:08 ET | 220 | 4.085 |
| 01:09 ET | 950 | 4.09 |
| 01:11 ET | 900 | 4.0849 |
| 01:13 ET | 1200 | 4.09 |
| 01:15 ET | 520 | 4.09 |
| 01:18 ET | 105 | 4.0809 |
| 01:22 ET | 550 | 4.09 |
| 01:27 ET | 40067 | 4.05 |
| 01:29 ET | 846 | 4.045 |
| 01:31 ET | 2025 | 4.055 |
| 01:33 ET | 800 | 4.055 |
| 01:36 ET | 300 | 4.055 |
| 01:38 ET | 350 | 4.06 |
| 01:40 ET | 500 | 4.0599 |
| 01:42 ET | 600 | 4.0503 |
| 01:44 ET | 534 | 4.052 |
| 01:45 ET | 400 | 4.05 |
| 01:47 ET | 2847 | 4.055 |
| 01:49 ET | 1507 | 4.05 |
| 01:51 ET | 7568 | 4.07 |
| 01:54 ET | 1100 | 4.08 |
| 01:56 ET | 600 | 4.075 |
| 01:58 ET | 500 | 4.075 |
| 02:00 ET | 400 | 4.07 |
| 02:02 ET | 1700 | 4.07 |
| 02:03 ET | 900 | 4.07 |
| 02:05 ET | 2644 | 4.065 |
| 02:07 ET | 100 | 4.07 |
| 02:09 ET | 100 | 4.065 |
| 02:12 ET | 100 | 4.07 |
| 02:14 ET | 3518 | 4.08 |
| 02:16 ET | 4348 | 4.08 |
| 02:18 ET | 300 | 4.075 |
| 02:20 ET | 200 | 4.075 |
| 02:21 ET | 1100 | 4.08 |
| 02:23 ET | 1242 | 4.08 |
| 02:25 ET | 900 | 4.085 |
| 02:27 ET | 100 | 4.085 |
| 02:30 ET | 6100 | 4.085 |
| 02:32 ET | 2107 | 4.06 |
| 02:34 ET | 300 | 4.065 |
| 02:36 ET | 486 | 4.0609 |
| 02:38 ET | 300 | 4.07 |
| 02:39 ET | 1072 | 4.06 |
| 02:41 ET | 10495 | 4.05 |
| 02:43 ET | 1100 | 4.055 |
| 02:45 ET | 200 | 4.06 |
| 02:48 ET | 2367 | 4.055 |
| 02:50 ET | 3031 | 4.0659 |
| 02:52 ET | 100 | 4.065 |
| 02:54 ET | 1584 | 4.065 |
| 02:56 ET | 300 | 4.065 |
| 02:57 ET | 600 | 4.065 |
| 02:59 ET | 700 | 4.065 |
| 03:01 ET | 559 | 4.0659 |
| 03:03 ET | 300 | 4.065 |
| 03:06 ET | 1224 | 4.065 |
| 03:08 ET | 400 | 4.065 |
| 03:10 ET | 4816 | 4.07 |
| 03:12 ET | 300 | 4.075 |
| 03:14 ET | 500 | 4.07 |
| 03:15 ET | 2417 | 4.055 |
| 03:17 ET | 7042 | 4.08 |
| 03:19 ET | 4980 | 4.08 |
| 03:21 ET | 3423 | 4.095 |
| 03:24 ET | 48549 | 4.0861 |
| 03:26 ET | 3551 | 4.08 |
| 03:28 ET | 3100 | 4.085 |
| 03:30 ET | 200 | 4.08 |
| 03:32 ET | 3795 | 4.055 |
| 03:33 ET | 1125 | 4.05 |
| 03:35 ET | 10324 | 4.05 |
| 03:37 ET | 900 | 4.05 |
| 03:39 ET | 4626 | 4.055 |
| 03:42 ET | 5690 | 4.055 |
| 03:44 ET | 5183 | 4.06 |
| 03:46 ET | 400 | 4.065 |
| 03:48 ET | 5244 | 4.06 |
| 03:50 ET | 12843 | 4.045 |
| 03:51 ET | 7505 | 4.025 |
| 03:53 ET | 2490 | 4.025 |
| 03:55 ET | 2191 | 4.025 |
| 03:57 ET | 18914 | 4.015 |
| 04:00 ET | 50797 | 4.01 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mereo BioPharma Group PLC | 658.5M | -15.2x | --- |
Stoke Therapeutics Inc | 677.1M | -6.0x | --- |
AnaptysBio Inc | 654.4M | -3.1x | --- |
SS Innovations International Inc | 683.0M | -25.1x | --- |
Immunome Inc | 696.0M | -2.3x | --- |
Oric Pharmaceuticals Inc | 663.8M | -5.4x | --- |
Company Information
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development. Etigilimab is an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity. Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late line ovarian cancer.
Contact Information
- Headquarters
- One Cavendish Place, Fourth FloorLONDON, United Kingdom W1G0QF
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Director
- Michael Wyzga
- Chief Executive Officer, Director
- Denise Scots-Knight
- Chief Financial Officer
- Christine Fox
- Senior Vice President - Clinical Development
- Suba Krishnan
- Senior Vice President - Therapeutic Head
- Jackie Parkin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $658.5M |
|---|---|
Revenue (TTM) | $1.2M |
Shares Outstanding | 153.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.01 |
EPS | $-0.26 |
Book Value | $0.36 |
P/E Ratio | -15.2x |
Price/Sales (TTM) | 543.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,918.95% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
